Market Place
Sourcing Support
CSL Vifor floats £23M offer to end competition probe in UK
11 Dec 2024 //
FIERCE PHARMA
CSL Vifor floats £23M offer to end competition probe in UK
10 Dec 2024 //
FIERCE PHARMA
Memo Therapeutic Appoints Frits Alphen as Chief Development Officer
04 Nov 2024 //
GLOBENEWSWIRE
Travere And CSL Announce Approval Of FILSPARI® For IgA Nephropathy
17 Oct 2024 //
GLOBENEWSWIRE
Veltassa Approved In Japan For Adult Hyperkalemia Treatment
23 Sep 2024 //
PR NEWSWIRE
EU antitrust regulators accept Vifor Pharma`s pledge not to disparage rival
23 Jul 2024 //
REUTERS
CordenPharma invests $981M to boost GLP-1 manufacture capacity
17 Jul 2024 //
FIERCEPHARMA
Vifor Pharma offers to fix alleged anti-competitive behaviour
20 Apr 2024 //
REUTERS
Vafseo® Approved by The U.S. Fda for The Treatment of Anemia
28 Mar 2024 //
PR NEWSWIRE
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia
19 Mar 2024 //
PR NEWSWIRE
Travere drug for rare kidney condition recommended for EU approval
24 Feb 2024 //
REUTERS
Vifor, CSL`s latest acquisition, struggles on multiple fronts
14 Feb 2024 //
FIERCE PHARMA
CSL Vifor calls for access to iron deficiency diagnosis and treatment
24 Nov 2023 //
PR NEWSWIRE
Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
28 Aug 2023 //
PR NEWSWIRE
Vifor`s Tavneos (avacopan) Receives Approval in Europe
19 Jul 2023 //
EMA
Kapruvia recommended by NICE for the treatment of CKD-associated pruritus
19 May 2023 //
PR NEWSWIRE
Tavneos included in updated EULAR recommendations for the management of AAV
27 Mar 2023 //
PR NEWSWIRE
Vifor Pharma`s Tavneos (Avacopan) Approved In Europe
13 Feb 2023 //
EMA
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
14 Dec 2022 //
BUSINESSWIRE
Vifor`s Velphoro Receives Approval in Europe
08 Dec 2022 //
EMA
Vifor`s Tavneos (Avacopan) Receives Approval in the Europe
25 Nov 2022 //
EMA
Two Aurinia execs are out — and CRISPR’s operations chief isn`t far behind
28 Oct 2022 //
ENDPTS
Approval of extension of exemptions from SIX disclosure & publicity obligations
20 Oct 2022 //
BUSINESSWIRE
Approval of delisting of Vifor Pharma AG`s registered shares
12 Oct 2022 //
BUSINESSWIRE
EMA accepts review of CSL Vifor & Travere`s cMAA for sparsentan
22 Aug 2022 //
BUSINESSWIRE
Vifor wins a few more years of protection from a potential Velphoro generic
22 Aug 2022 //
ENDPTS
Kapruvia approved in Switzerland with additional regulatory decisions
19 Aug 2022 //
GLOBENEWSWIRE
CSL CEO determined to grow plasma collection after full-year sales dip
17 Aug 2022 //
ENDPTS
Tavneos recommended by England’s NICE for the treatment of AAV (GPA/MPA)
17 Aug 2022 //
BUSINESSWIRE
CSL clears regulatory hurdles to settle $16.4b buyout of Vifor
02 Aug 2022 //
THEWEST
5 pharmas lambasted by UK watchdog for marketing snafus
01 Aug 2022 //
FIERCEPHARMA
Extension of the postponement of the settlement of Vifor Pharma tender offer
13 Jul 2022 //
BUSINESSWIRE
Regulatory approvals delay CSL`s $11.7B takeover of Vifor
13 May 2022 //
AFR
CSL share price cracks under Vifor Pharma acquisition delay
11 May 2022 //
FOOL
94th Vifor Pharma Group Annual General Meeting
26 Apr 2022 //
BUSINESSWIRE
Veltassa enables patients to achieve potassium control, optimized RAASi therapy
04 Apr 2022 //
BUSINESSWIRE
Publication of definitive end result for Vifor Pharma tender offer
28 Mar 2022 //
BUSINESSWIRE
Publication of provisional end result for Vifor Pharma tender offer
22 Mar 2022 //
BUSINESSWIRE
Result for Vifor Pharma tender offer: CSL Behring declares offer successful
07 Mar 2022 //
BUSINESSWIRE
Publication of provisional interim result for Vifor Pharma tender offer
02 Mar 2022 //
BUSINESSWIRE
Akebia scrapes together $85M war chest to commercialize vada as PDUFA date looms
24 Feb 2022 //
ENDPTS
Akebia Tx Announces Amendment of License Agreement with Vifor Pharma
22 Feb 2022 //
PRESS RELEASE
Akebia Therapeutics Announces Amendment of License Agreement with Vifor
22 Feb 2022 //
PRESS RELEASE
Vifor Pharma reports sustained growth in 2021
17 Feb 2022 //
BUSINESSWIRE
Vifor Pharma appoints two new members to the Executive Committee
02 Feb 2022 //
BUSINESSWIRE
CordenPharma Acquires Three Manufacturing Facilities from Vifor Pharma
01 Feb 2022 //
PRNEWSWIRE
CSL publishes Offer Prospectus on public tender offer for all shares of Vifor
18 Jan 2022 //
BUSINESSWIRE
Vifor`s hyperkalaemia drug Veltassa shows benefit in heart failure patients
21 Dec 2021 //
BUSINESSWIRE
Vifor reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa
20 Dec 2021 //
BUSINESSWIRE
Vifor, American Regent announce settlement of Injectafer patent litigation
19 Dec 2021 //
BUSINESSWIRE
Vifor Pharma Drives Transformation with Divestment of Non-Core Finished Drug
17 Dec 2021 //
CORDENPHARMA
CSL and Vifor Confirm Advanced Talks of Potential $8 Billion+ Acquisition
14 Dec 2021 //
BIOSPACE
Merck`s HIV Trials Put On Clinical Hold, Vifor Gets A Suitor, VERU Scores FDA
13 Dec 2021 //
KOREABIOMED
Vifor Pharma shares jump 15% as takeover talks with CSL confirmed
11 Dec 2021 //
FXEMPIRE
Vifor Pharma appoints Hervé Gisserot as new CCO &member of the Ex Committee
11 Dec 2021 //
VIA
Vifor poaches new chief commercial officer from GSK
11 Dec 2021 //
FIERCEPHARMA
Vifor Pharma and Angion report topline results from phase-II trial of ANG-3777
10 Dec 2021 //
BUSINESSWIRE
First patient enrolled in phase-IIa study of vamifeport in sickle cell disease
10 Dec 2021 //
BUSINESSWIRE
Angion &Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777
09 Dec 2021 //
GLOBENEWSWIRE
Australian biotech giant CSL set to buy Vifor for $7.1B: report
03 Dec 2021 //
REUTERS
